Related Experiment Video
Updated: Feb 8, 2026

Author Spotlight: Advancing Labor Management Through Electromyometrial Imaging for Understanding Uterine Contractions
Published on: May 26, 2023
Immunization Against Group B Streptococci vs. Intrapartum Antibiotic Prophylaxis in Peripartum Pregnant Women and
Mariya Kristeva1, Catherine Tillman1, Ashley Goordeen1
1University of Central Florida College of Medicine, Orlando, USA.
Insights
A new vaccine for Group B Streptococcus (GBS) shows promise in protecting newborns from sepsis, meningitis, and pneumonia. This GBS vaccine offers an alternative to intrapartum antibiotics, especially for women unable to complete treatment or in resource-poor settings.
Area of Science:
- Obstetrics and Gynecology
- Neonatal Health
- Infectious Diseases
Background:
- Group B Streptococcus (GBS) significantly impacts neonatal morbidity and mortality globally.
- GBS colonizes pregnant women, transmitting to neonates during delivery, causing severe infections like sepsis, meningitis, and pneumonia.
- Current intrapartum antibiotic prophylaxis for GBS has limitations, including treatment duration, antibiotic resistance, and lack of late-onset disease coverage.
Purpose of the Study:
- To explore alternative GBS prophylaxis methods, focusing on vaccination.
- To evaluate the efficacy and safety of an investigational CRM197 conjugated trivalent GBS vaccine.
- To assess the vaccine's potential to supplement current antibiotic prophylaxis guidelines.
Main Methods:
- Investigated an investigational CRM197 conjugated trivalent GBS vaccine.
- Assessed vaccine immunogenicity against the three most prevalent GBS serotypes.
- Evaluated antibody transfer across the placenta and persistence in neonates, alongside safety profile.
Main Results:
- The GBS vaccine demonstrated good immunogenicity against the three most prevalent serotypes.
- Induced antibodies crossed the placenta and persisted in neonates for up to 90 days.
- The vaccine exhibited a favorable safety profile with no serious systemic adverse effects, only mild injection site pain.
Conclusions:
- The investigational GBS vaccine shows potential as an effective supplement to intrapartum antibiotic prophylaxis.
- It offers advantages for women with antibiotic resistance, those unable to complete antibiotic courses, and in resource-poor settings.
- Future research should focus on maternal colonization effects, broader serotype coverage, and use in resource-limited areas.
Abstract:
Group B streptococcus (GBS) is an organism that has an immense global impact on neonatal morbidity and mortality. GBS is known to colonize the gastrointestinal and genitourinary tracts of infected pregnant women. Transmission to the neonate is achieved during labor and delivery. Complications of neonatal infection include sepsis, meningitis, and pneumonia. Preventative measures are needed to reduce the disease burden. The current method of prophylaxis being utilized is intrapartum antibiotics. Though effective, it presents limitations that include a required, lengthy duration of treatment, increased antibiotic resistance, and lack of late-onset disease coverage. Recent studies are exploring alternative methods of prophylaxis such as vaccination. Vaccination provides coverage of both early and late-onset disease to infected women who are unable to complete the required four hours of antibiotic course intrapartum, women with resistance to antibiotic infections, and women delivering in resource-poor areas without access to antibiotics. An investigational CRM197 conjugated trivalent vaccine has shown a good immunogenicity profile against the three most prevalent serotypes. The vaccine induced antibodies freely cross the placenta and persist in a neonate for up to 90 days after birth. Additionally, the vaccine possesses a safety profile free of any serious systemic adverse effects and only mild pain at the injection site. Future studies should focus on investigating the effect of the vaccine on maternal rectovaginal acquisition and subsequent vaginal colonization, as well as the expansion of vaccine coverage to all 10 serotypes identified worldwide in order to facilitate its use in resource-poor areas of the world with inadequate antibiotic availability. If available, such a vaccine can serve as an effective supplement to current guidelines of antibiotic prophylaxis against GBS in peripartum women and their neonates.
Related Concept Videos
Antibiotic Selection
Review and Preview
Percentiles are a type of fractile that partition data into...
Review and Preview
What is the Immune System?
Development of Antibiotic Resistance
Humoral Immune Responses

